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Background-—The recent introduction of high-sensitivity cardiac troponin (hs-cTn) assays has allowed clinicians to measure hs-cTn
before and after cardiac stress testing, but the hs-cTn release pattern and potential utility in identifying inducible myocardial
ischemia are unclear. We thus conducted a systematic review and meta-analysis to improve our understanding of hs-cTn release
associated with exercise and pharmacological stress testing.
Methods and Results-—Studies published between January 2008 and July 2016 that reported hs-cTn change values (high-
sensitivity cardiac troponin T [hs-cTnT] or high-sensitivity cardiac troponin I [hs-cTnI]) in relation to cardiac stress testing were
searched and reviewed by 2 independent screeners. Primary outcomes were pooled estimates of absolute and relative hs-cTn
changes after cardiac stress test, stratiﬁed by the presence of inducible myocardial ischemia. This meta-analysis included 11
studies (n=2432 patients). After exercise stress testing, hs-cTnT increased by 0.5 ng/L or 11% (6 studies, n=406) and hs-cTnI
by 2.4 ng/L or 41% (4 studies, n=365) in patients with inducible myocardial ischemia versus hs-cTnT by 1.1 ng/L or 18% (8
studies, n=629; P=0.29) and hs-cTnI by 1.8 ng/L or 72% (4 studies, n=831; P=0.61) in patients who did not develop inducible
myocardial ischemia. After pharmacological stress test, hs-cTnT changed by 0.1 ng/L or 0.4% (6 studies, n=251) and hs-
cTnI by 2.4 ng/L or 32% (2 studies, n=108) in patients with inducible myocardial ischemia versus hs-cTnT by 0.7 ng/L or 11%
(5 studies, n=443, P=0.44) and hs-cTnI by 1.7 ng/L or 38% (2 studies, n=116; P=0.62) in patients who did not develop
inducible myocardial ischemia.
Conclusions-—hs-cTn rising patterns after exercise and pharmacological stress testing appear inconsistent and comparably small,
and do not appear to be correlated with inducible myocardial ischemia. ( J Am Heart Assoc. 2019;8:e008626. DOI: 10.1161/
JAHA.118.008626)
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H igh-sensitivity cardiac troponin (hs-cTn) assays havereplaced contemporary cardiac troponin (cTn) assays
throughout most of the world and continue to enhance our
understanding of the pathophysiology of myocardial infarc-
tion, ischemia, and injury. In most adult patients, hs-cTn
assays have the ability to detect cTn at low concentrations
and consequently to identify much smaller change values.1
For instance, multiple studies have found signiﬁcant cTn
increases following strenuous physical activity and cardiovas-
cular stress.2–6
Of particular relevance to cardiovascular medicine are
cardiac biomarker elevations associated with cardiac stress
testing. Cardiac biomarkers have the potential to increase
the clinical utility of cardiac stress testing if they are able
to identify high-risk patients who do not have an
unequivocal stress test result. However, there is currently
no consensus regarding the mechanism or diagnostic
utility of hs-cTn release during and after cardiac stress
testing.7
To improve our understanding about hs-cTn release
associated with cardiac stress testing, we conducted a
systematic review of the existing literature and performed a
meta-analysis.
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Materials and Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. This systematic review
and meta-analysis was performed following the guidelines of
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analysis).8
Search Strategy
We searched the published literature using strategies created
by a medical librarian for published evidence on hs-cTn and
exercise or pharmacological stress testing with a publication
cutoff date of June 30, 2016. To exclude animal studies, the
librarian used the human ﬁlter for Medline recommended in
the Cochrane Handbook for Systematic Reviews of Interven-
tions9 and modiﬁed it to create similar ﬁlters for the other
databases searched. The librarian established search strate-
gies using a combination of standardized terms and key
words, and implemented it in Ovid Medline, Embase, Scopus,
Cochrane Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials, Database of Abstracts of
Reviews of Effects, Health Technology Assessments, and the
NHS Economic Evaluation Database. We also conducted a
search in clinicaltrials.gov. We searched for all studies in
which high-sensitivity cardiac troponin T (hs-cTnT) or high-
sensitivity cardiac troponin I (hs-cTnI) were evaluated before
and after cardiac stress testing. Key words were “stress,”
“adenosine,” “dobutamine,” “troponin T,” “troponin I,” and
“high-sensitivity troponin.” Two authors systematically
screened titles and abstracts of studies identiﬁed in the
search and excluded unrelated studies independently. More-
over, they veriﬁed the remaining full articles and reference
lists.
Eligibility Criteria
The article or abstract was included in this meta-analysis if it
met the following criteria: (1) original article or abstract that
evaluated the association between cardiac stress testing and
hs-cTn; and (2) hs-cTn was measured before and after
exposure cardiac stress testing. Since hs-cTn assays have
been introduced only during the past decade, we excluded all
records before 2008. Articles or abstracts were excluded if
the study population included patients who had active
symptoms of myocardial ischemia or infarction, such as
discomfort, pain, stress, or increased physical activity before
the ﬁrst hs-cTn concentration was measured. Review articles,
case reports, and studies without reference interval values for
troponin were also excluded. If multiple publications over-
lapped or were duplicated, the most comprehensive study
was used to extract the information needed.
Selection of Articles
Our literature search revealed 4221 articles and abstracts;
759 duplicates were accurately identiﬁed and removed for a
total of 3462 unique citations. After screening titles and
abstracts of articles, 57 records were reviewed with full texts.
Finally, 11 studies were included in the meta-analysis,3,5,6,10–17
and 46 were excluded because of incomplete or overlapping
data. The Figure shows details of the selection process for
studies. The collective methodological quality of included
studies was good, using the National Heart, Lung, and Blood
Institute (NHLBI) quality assessment tool for before–after
(pre–post) studies with no control group.
Data Extraction and Quality Assessment
The authors extracted data from included articles indepen-
dently and the results were cross-checked. Authors, years,
sample size, age, exercise or pharmacological stress test,
duration of exercise, detection assay, and mean values of hs-
cTnT and hs-cTnI levels measured before and after stress test
were extracted in each individual article (Table 1). Authors
were contacted by email if the required data were unavailable.
We applied the NHLBI quality assessment tool for before–
after (pre–post) studies with no control group18 to assess the
quality of eligible studies. Methodological quality of eligible
studies was assessed independently. Any disagreements were
resolved by discussions or by consensus including the senior
author. All studies were separated into groups according to
type of cardiac stress test (exercise or pharmacological stress
test) and troponin type (hs-cTnT or hs-cTnI). Furthermore,
patients who developed myocardial ischemia (“positive stress
test”) and those who did not were analyzed separately. The
only exception was for the studies by LeGoff et al11 and Kurz
et al,10 which did not distinguish between hs-cTn values of
Clinical Perspective
What Is New?
• In this systematic review and meta-analysis analyzing high-
sensitivity cardiac troponin kinetics in patients undergoing
exercise or pharmacological stress testing, high-sensitivity
cardiac troponin rising patterns after exercise or pharma-
cological cardiac stress testing were inconsistent, compa-
rably small, and did not correlate with inducible myocardial
ischemia.
What Are the Clinical Implications?
• We found little evidence to support the utility of high-
sensitivity cardiac troponin in improving the diagnostic
utility in cardiac stress testing.
DOI: 10.1161/JAHA.118.008626 Journal of the American Heart Association 2
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exercise and pharmacological stress tests (we thus added the
data to both exercise and pharmacological stress test
analyses).
Statistical Analysis
If an hs-cTn value was not exactly reported, we used the
closest lowest/highest value (eg, 4.9 instead of <5). Ranges
or interquartile ranges were converted into SDs as described
by Wan et al19 to be able to compute pooled estimates in the
meta-analysis. The mean/median hs-cTn change from base-
line was computed as the difference between peak values
after exercise or stress test and baseline values, as well as the
standard error, using the Comprehensive Meta-Analysis
software package (version 3.3, Biostat). If missing, a corre-
lation coefﬁcient between pre- and post-values of 0.3 was
assumed.20 The CIs for relative change from baseline values
were calculated using GraphPad software (GraphPad Software
Inc). Random-effects meta-analyses of the absolute and
relative changes from baseline were computed. We used the
I2 and Cochran Q statistics to assess the heterogeneity of
results across studies. A subgroup analysis was conducted by
systematically excluding each study at a time and rerunning
the analysis to assess any change in effect size. We compared
results between patients who developed myocardial ischemia
versus those who did not (“positive” versus “negative” stress
test) using a Q test based on analysis of variance applying
random-effects weights (mixed effects analysis) in the Com-
prehensive Meta-Analysis software package.
Results
This meta-analysis included 11 studies with a total of 2432
participants, 11 studies (n=1729) evaluating hs-cTnT, and 4
studies (n=1420) evaluating hs-cTnI (Figure). Baseline char-
acteristics of the included studies are shown in Table 1.
Table 2 provides an overview of the study results, and
Table S1 provides an assessment of the quality of the
included studies. Peak hs-cTn values were uniformly obtained
between 3 and 4 hours after stress test.
Exercise Stress Test
High-sensitivity cTnT
The pooled estimated absolute hs-cTnT change in patients
who developed inducible myocardial ischemia after exercise
stress test (“positive test”) was 0.5 ng/L (95% CI, 0.0–
0.9 ng/L), or a relative change of 11% (95% CI, 0–23%; 6
studies, n=406), compared with 1.1 ng/L (95% CI, 0.0–
2.2 ng/L), or a relative change of 18% (95% CI, 3–34%), in
patients who did not develop inducible myocardial ischemia
after exercise stress test (8 studies, n=629; P=0.29)
(Figure S1).
Table 1. Baseline Characteristics of the Studies Included in the Meta-Analysis
Study Country Population Type of Stress Assay
Axelsson 20133 Denmark 12 patients with CAD
and 12 healthy controls
Bicycle stress test Roche Elecsys hs-cTnT
Kurz 200810 Germany 144 patients with suspected CAD Bicycle or dipyridamole
stress test
Roche Elecsys hs-cTnT
Lee 201612 Switzerland 819 patients with suspected
myocardial ischemia
Bicycle SPECT Singulex hs-cTnI
Le Goff 201011 Belgium 50 patients with suspected CAD Bicycle or dipyridamole
stress test
Roche Elecsys hs-cTnT
Abbott Diagnostics Architect STAT hs-cTnI
Liebetrau 201513 Germany 383 patients with suspected
or progressive CAD
Bicycle stress test Roche Elecsys hs-cTnT
Pastormerlo 201314 Italy 23 patients with CHF Bicycle stress test Roche Elecsys hs-cTNT
Pastormerlo 20155 Italy 30 patients with systolic HF Bicycle stress test Roche Elecsys hs-cTnT
Rosjo 201215 Norway 198 patients Bicycle stress test Roche Elecsys hs-cTnT and Abbott Diagnostics
Architect STAT hs-cTnI
Sou 201616 Switzerland 229 patients with suspected CAD Bicycle stress test Roche Elecsys hs-cTNT and Abbott Diagnostics
Architect STAT hs-cTnI
Wongpraparut 20116 Thailand 120 patients with suspected CAD Pharmacologic stress MRI Roche Elecsys hs-cTNT
Wongpraparut 201517 Thailand 250 patients with suspected CAD Pharmacologic stress MRI Roche Elecsys hs-cTnT
CAD indicates coronary artery disease; CHF, chronic heart failure; HF, heart failure; hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T; MRI, magnetic
resonance imaging; SPECT, single-photon emission computed tomography.
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High-sensitivity cTnI
The pooled estimated absolute hs-cTnI change in patients who
developed inducible myocardial ischemia after exercise stress
test was 2.4 ng/L (95% CI, 0.2–4.7 ng/L), or a relative
change of 41% (95% CI, 4–79%; 4 studies, n=365), compared
with 1.8 ng/L (95% CI, 1–3 ng/L), which corresponded to a
relative change of 72% (95% CI, 31–113%) in patients who did
not develop inducible myocardial ischemia after exercise
stress test (4 studies, n=831; P=0.61) (Figure S2A).
Pharmacological Stress Test
High-sensitivity cTnT
The pooled estimated absolute hs-cTnT change in patients
who developed inducible myocardial ischemia after
pharmacological stress test was 0.1 ng/L (95% CI, 1.7 to
1.5 ng/L), which corresponded to a relative change of 5% (95%
CI,8 to 18%; 6 studies, n=251), compared with 0.7 ng/L (95%
CI, 0.5, 2 ng/L), which corresponded to a relative change of
11% (95% CI, 6 to 28%) in patients who did not develop
inducible myocardial ischemia (5 studies, n=443; P=0.44)
(Figure S3).
High-sensitivity cTnI
The pooled estimated absolute hs-cTnI change in patients who
developed inducible myocardial ischemia after pharmacolog-
ical stress was 2.4 ng/L (95% CI, 0.2–4.5 ng/L), which
represented a relative change of 32% (95% CI, 3 to 66%; 2
studies, n=108), compared with 1.7 ng/L (95% CI, 0.6–
2.9 ng/L), which represented a relative change of 38% (95%
Figure. Flow diagram summarizing study identiﬁcation and selection. hs-cTn indicates high-sensitivity
cardiac troponin.
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CI, 4–71%), in patients who did not develop inducible
myocardial ischemia after exercise stress testing (2 studies,
n=116; P=0.62) (Figure S4).
Discussion
The goal of this systematic review and meta-analysis was to
obtain and quantify the available evidence regarding hs-cTn
release after cardiac stress testing. We distinguished between
exercise and pharmacological stress tests. Additionally, we
sought to determine whether hs-cTn release is more pro-
nounced among patients with inducible myocardial ischemia
during stress test compared with patients who do not develop
myocardial ischemia, which could have diagnostic utility.
The results of this study indicate that hs-cTnT and hs-cTnI
release after cardiac stress testing is modest in magnitude and
on average ranges from 0 to 2 ng/L for absolute change values.
Relative change values appear to be smaller for hs-cTnT (median
range 5–18%) compared with hs-cTnI (median range, 32–72%).
There was no statistically signiﬁcant difference in hs-cTn
release between patients who developed inducible myocardial
ischemia versus those who did not. In fact, given the low
baseline values in most patients, these values do not exceed
conjoint biological and analytical variation.21
The concept that the addition of cardiac biomarker data to
cardiac stress testing may improve diagnostic utility is not new
and has been tested in several studies. In general, studies have
found that low baseline values are highly predictive of a
negative stress test. For example, Lee et al12 showed that a
baseline hs-cTnI value <1.5 ng/L had an 87% negative
predictive value for inducible myocardial ischemia after stress
test. Furthermore, patients with inducible myocardial ischemia
were found to have higher baseline hs-cTn values in
most,7,12,13,15,16 but not all, studies.10 Interestingly, our
analysis showed smaller relative changes in hs-cTn levels in
patients with inducible ischemia when compared with those
without inducible ischemia.
Difference Between hs-cTnT and hs-cTnI
The results of this study suggest that the release of hs-cTnT
after stress testing may be substantially smaller compared
with hs-cTnI. While it is possible that cardiac stress releases
different quantities of hs-cTnI and hs-cTnT, it appears unlikely
and biologically somewhat implausible. Stress that damages
the cardiomyocyte cell membrane should result in simultane-
ous release of cTnI and cTnT, the quantities of which should
be tightly correlated. A more logical explanation for the
apparent discrepancy between hs-cTnT and hs-cTnI results
may be related to the calibration of the assays and their
sensitivity and precision at low values. Another possible
explanation may be related to the rhythmic diurnal variation of
hs-cTnT, which shows higher levels in the morning and at
nighttime and lower levels during the day.22–24 While rhythmic
diurnal variation is characteristic for hs-cTnT, it has not been
observed in hs-cTnI.
cTn Release During Stress Test
cTn is highly speciﬁc for myocardial tissue. Any process that
causes injury to cardiomyocytes including myocardial infarc-
tion will cause an elevation of cTn in the blood stream. Until
recently—before the introduction of hs-cTn assays—it was
widely assumed that cTn is only released during myocardial
Table 2. Absolute and Relative Change Values
No Ischemia Ischemia P Value
Exercise stress test—hs-cTnT
Absolute change, ng/L 1.1 (0–2.2) 0.5 (0–0.9) 0.29
Relative change, % 18 (3–34) 11 (0.3 to 23) 0.48
Exercise stress test—hs-cTnI
Absolute change, ng/L 1.8 (0.6–3) 2.4 (0.2–4.7) 0.61
Relative change, % 72 (31–113) 41 (3–79) 0.28
Pharmacologic stress test—hs-cTnT
Absolute change, ng/L 0.7 (0.5 to 1.9) 0.1 (1.7 to 1.5) 0.44
Relative change, % 11 (6 to 28) 5 (8 to 18) 0.59
Pharmacologic stress test—hs-cTnI
Absolute change, ng/L 1.7 (0.6–2.9) 2.4 (0.2–4.5) 0.62
Relative change, % 38 (4–71) 32 (3–66) 0.81
Values are expressed as pooled estimates from the meta-analysis and corresponding 95% CIs.
hs-cTnI indicates high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T.
DOI: 10.1161/JAHA.118.008626 Journal of the American Heart Association 5
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cell necrosis. Recent hs-cTn data, however, have strongly
questioned this assumption. Data obtained from young,
healthy athletes have shown that hs-cTn levels may rise
several-fold after strenuous exercise. Likewise, an intravenous
infusion of dobutamine or rapid atrial pacing will lead to a rise
in hs-cTn concentrations. In experimental models, hs-cTnI
release has been documented with transient ischemia and
caused by volume loading.25 In these models, the myocardial
cells die as a result of apoptosis.26 Thus, although speculative,
during cardiac stress testing, several potential mechanisms
may contribute to hs-cTn increase other than myocardial cell
necrosis such as inducible myocardial ischemia, transient
increases in cardiomyocyte permeability,27–29 ischemic-
induced membranous blebs that rupture without necrosis,30
free radical overload,31 increased turnover of troponins,32 and
direct toxic effects of catecholamines. However, this topic is
controversially discussed.
Limitations
This study focused on hs-cTn change values and did not
investigate the ability of baseline values (low or high) to
predict inducible myocardial ischemia during stress test.
Second, we did not distinguish between individual hs-cTn
assays and platforms that were used in each study. Third,
cardiac biomarker research and development in industry is
currently occurring at a fast pace, and thus there may have
been temporal trends inﬂuencing the study (older versus
newer assays, reagents, and platforms). From a statistical
standpoint, we had to convert median and range values to
means and SDs, which may have inﬂuenced some results.
Conclusions
Results from this meta-analysis suggest that hs-cTn rising
patterns after exercise and pharmacological stress testing
appear inconsistent and comparably small and do not appear
to be correlated with inducible myocardial ischemia. These
results cast doubt on the idea that rising patterns of hs-cTn
may be used to stratify patients after cardiac stress testing.
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Axelsson 20131 Y Y Y Y NR Y Y NR Y Y Y Y 
Kurz 20082 Y N Y Y Y Y Y Y Y Y Y Y 
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Sou 20169 Y Y Y Y Y Y Y Y Y Y Y NR 
Wongpraparut 201110 Y Y Y Y Y Y Y Y Y Y Y NA 
Wongpraparut 201511 Y Y Y Y Y Y Y Y Y Y Y NA 
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Figure S1. Pooled estimates of the absolute and relative hs-cTnT change from baseline 
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Figure S2. Pooled estimates of the absolute hs-cTnI change from baseline after exercise 
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Figure S3. Forest plot showing pooled estimate of the absolute hs-cTnT change from 
baseline after pharmacological stress testing in patients without (a) and with (b) 
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Figure S4. Forest plot showing pooled estimate of the absolute hs-cTnI change from 
baseline after pharmacological stress testing in patients without (a) and with (b) 
inducible myocardial ischemia. No funnel plots to assess publication bias could be 
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